Category: 58-97-9

Walter, Patrick; Mechaly, Ariel; Bous, Julien; Haouz, Ahmed; England, Patrick; Lai-Kee-Him, Josephine; Ancelin, Aurelie; Hoos, Sylviane; Baron, Bruno; Trapani, Stefano; Bron, Patrick; Labesse, Gilles; Munier-Lehmann, Helene published the artcile< Structural basis for the allosteric inhibition of UMP kinase from Gram-positive bacteria, a promising antibacterial target>, Recommanded Product: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate, the main research area is allostery; cryo-EM single particle analysis; crystal structure; enzyme regulation; nucleotide metabolism.

Tuberculosis claims significantly more than one million lives each year. A feasible way to face the issue of drug resistance is the development of new antibiotics. Bacterial UMP (UMP) kinase is a promising target for novel antibiotic discovery as it is essential for bacterial survival and has no counterpart in human cells. The UMP kinase from M. tuberculosis is also a model of particular interest for allosteric regulation with two effectors, GTP (pos.) and UTP (neg.). In this study, using X-ray crystallog. and cryo-electron microscopy, we report for the first time a detailed description of the neg. effector UTP-binding site of a typical Gram-pos. behaving UMP kinase. Comparison between this snapshot of low affinity for Mg-ATP with our previous 3D-structure of the GTP-bound complex of high affinity for Mg-ATP led to a better understanding of the cooperative mechanism and the allosteric regulation of UMP kinase. Thermal shift assay and CD experiments corroborate our model of an inhibition by UTP linked to higher flexibility of the Mg-ATP-binding domain. These new structural insights provide valuable knowledge for future drug discovery strategies targeting bacterial UMP kinases.

FEBS Journal published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Recommanded Product: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Due, Ong The; Chaikledkaew, Usa; Genuino, Anne Julienne M.; Sobhonslidsuk, Abhasnee; Thakkinstian, Ammarin published the artcile< Systematic Review with meta-analysis: efficacy and safety of direct-acting antivirals for chronic hepatitis C genotypes 5 and 6>, Recommanded Product: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate, the main research area is chronic hepatitis C genotype direct acting antiviral metaanalysis.

Direct-acting antivirals (DAAs) are modern treatments for chronic hepatitis C infection, but majority of available evidence on its treatment effect covers genotypes 1 to 4. Therefore, the efficacy and safety of DAAs for genotypes 5 and 6 need to be analyzed. Studies were identified from Medline, Scopus, and CENTRAL and a Chinese database CNKI, from inception until Dec 4, 2018. Clin. trials were included if they enrolled patients with genotypes 5 and/or 6 infection, any type of second-generation DAAs was studied, and sustained virol. response was assessed at the 12th week after treatment (SVR12) as outcome measure. Metaanal. using metaprop statistical program was applied for pooling proportions if data were sufficient (i.e., at least 2 studies). Thirteen studies were included in the anal. Four studies assessed the efficacy of four DAA regimens in genotype 5 patients, which were mainly sofosbuvir (SOF) plus pegylated-interferon/ribavirin (PR) or other DAAs, with SVR12 ranging from 94.4% to 100%. Twelve studies assessed the efficacy of seven DAA regimens among genotype 6 patients, but only two DAA regimens (i.e., SOF + PR and SOF/ledipasvir) had sufficient data for pooling. The pooled SVR12 rates (95% CI) were 99.6% (92.2 to 100) for SOF + PR and 99.2% (96.5 to 100) for SOF/ledipasvir. No treatment-related serious adverse event was reported, while the nonserious adverse events were comparable to other genotypes. In conclusion, DAAs are effective and may be safe for the treatment of chronic hepatitis C genotypes 5 and 6. However, our evidence is based on noncomparative studies; hence, further larger-scale randomized controlled trials in these genotypes are still required.

BioMed Research International published new progress about Antiviral agents. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Recommanded Product: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Lens, Sabela; Lazarus, Jeffrey V published the artcile< The paediatric population: the forgotten element to eliminating hepatitis C virus.>, Recommanded Product: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate, the main research area is .

There is no abstract available for this document.

The lancet. Gastroenterology & hepatology published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Recommanded Product: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Shirali, Aditya S; Zagzag, Jonathan; Chiang, Yi-Ju; Huang, He; Zhang, Miao; Habra, Mouhammed Amir; Grubbs, Elizabeth G; Fisher, Sarah B; Perrier, Nancy D; Lee, Jeffrey E; Graham, Paul H published the artcile< Differences in Clinicopathologic Behavior of Oncocytic Adrenocortical Neoplasms and Conventional Adrenocortical Carcinomas.>, Electric Literature of 58-97-9, the main research area is .

BACKGROUND: Oncocytic adrenocortical neoplasms (OANs) are rare endocrine tumors that present as a spectrum from benign to malignant. The outcomes after surgical resection of the oncocytic variant of adrenocortical carcinoma remain poorly understood. We sought to characterize the clinicopathologic features of OAN and compare oncocytic adrenocortical carcinoma (OAC) with conventional adrenocortical carcinoma (ACC). PATIENTS AND METHODS: Adult patients who underwent adrenalectomy for OAN or ACC between January 1990 and September 2020 were identified. Demographics, clinicopathologic factors, American Joint Committee on Cancer stage, and cancer-related outcomes were reviewed. A matched cohort analysis of disease-free survival (DFS) and overall survival (OS) was performed between patients with OACs and those with ACCs. RESULTS: Forty-one patients with OAN and 214 patients with ACC were included. The OAN cohort median age was 45.2 years [interquartile ratio (IQR) 38.5-54.0 years], and 61.0% were female. OANs were benign (n = 11), of uncertain malignant potential (UMP, n = 9), or OAC (n = 21). Disease recurrence occurred in 12 (57.1%) patients with OAC compared with 1 (11.1%) and 0 patients with UMP or benign OAN, respectively (p < 0.001). Seven (33.3%) patients with OAC died during follow-up compared with 0 patients with UMP or benign OAN (p = 0.020). Kaplan-Meier survival analysis found no difference in DFS between ACC and OAC groups before (p = 0.218) and after 2:1 matching (p = 0.417). Overall survival was shorter for patients who had ACC compared with those who had OAC (p = 0.031), but the difference was not evident with matched analysis (p = 0.200). CONCLUSIONS: OAN presents as a spectrum from benign indolent tumors to aggressive carcinomas. OACs demonstrate similar clinicopathologic behavior and recurrence-free and overall survival when matched to conventional ACCs. Annals of surgical oncology published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Electric Literature of 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Xie, Chun-yan; Wang, Qinhua; Li, Guanya; Fan, Zhiyong; Wang, Hong; Wu, Xin published the artcile< Dietary supplement with nucleotides in the form of uridine monophosphate or uridine stimulate intestinal development and promote nucleotide transport in weaned piglets>, Category: tetrahydrofurans, the main research area is piglet UMP uridine dietary supplement intestine development nucleotide transport; intestinal development; uridine; uridine monophosphate; weaned piglets.

BACKGROUND : Nucleotides are key constituents of milk, where they are utilized in cell replication, although there are limited studies for weaned piglets. This study evaluated the effects of uridine monophosphate (UMP) with uridine (UR) feed supplementation on the intestinal development and nucleotide transport in weaned piglets. RESULTS : Supplementation with UMP significantly increased (P ≤ 0.05) plasma glucose, and UR supplementation significantly reduced (0.05 ≤ P ≤ 0.10) the plasma total cholesterol (TC) of piglets when compared with that of the control group, although non-significant difference (P ≥ 0.05) in growth performance was observed among three groups. Piglets fed supplementary UR exhibited greater (P ≤ 0.05) crypt depth in the duodenum and ileum when compared with those in the supplementary UMP and control groups. Real-time quant. polymerase chain reaction (RT-qPCR) results revealed that UR supplementation increased (P ≤ 0.05) the relative mRNA levels of genes encoding the transmembrane proteins ZO-1 and occludin in the duodenum mucosa, and ZO-1 in the jejunum mucosa (P ≤ 0.05). Similarly, UR supplementation increased (P ≤ 0.05) expression of solute carriers SLC28A1 and SLC29A1 in the duodenum mucosa. Conversely, claudin-1 expression in the duodenum mucosa was inhibited (P ≤ 0.05) by dietary supplementation with UMP or UR. CONCLUSION : Collectively, our data indicated that dietary supplementation with UMP or UR was conducive to stimulating intestinal development and promoting nucleotide transport in weaned piglets.

Journal of the Science of Food and Agriculture published new progress about Body weight. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Category: tetrahydrofurans.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Datta, Soumendra N; Chalokia, Ramandeep S; Wing, K W; Patel, K; Solanki, R; Desai, Janak published the artcile< Ultramini-percutaneous nephrolithotomy versus retrograde intrarenal surgery in the treatment of 10-30 mm calculi: a randomized controlled trial.>, HPLC of Formula: 58-97-9, the main research area is Minimal invasive management of renal calculi; Randomized controlled trial; Retrograde intrarenal surgery (RIRS); Ultramini-percutaneous nephrolithotomy (UMP).

The surgical management of renal stones 10-30 mm is usually performed with percutaneous nephrolithotomy (PCNL) and retrograde intrarenal surgery (RIRS). Standard form of percutaneous nephrolithotomy has paved the way for miniaturized PCNL in many centres. We wanted to evaluate the efficacy, safety and the cost-effectiveness of ultramini-percutaneous nephrolithotomy (UMP) versus RIRS in the treatment of renal stones with stone burden 10-30 mm. Patients with renal stone burden 10-30 mm were prospectively randomized into either UMP or RIRS. The demographic data, stone characteristic, operative time and cost of the equipment were recorded. The stone free status, analgesic requirement, deterioration of the renal function and hemoglobin and the postoperative complications as per Clavein-Dindo grade were recorded. One hundred and fifty patients met inclusion criteria. Out of these 98 underwent UMP and 46 RIRS. Six withdrew the consent before the procedure. Mean stone size was comparable in either of the groups. Mean laser time and stone extraction time was significantly less for UMP compared to RIRS (41.17 min versus 73.58 min p < 0.0001). Mean consumable costs in the UMP group were considerably less at US$45.73 compared to the RIRS group at $423.11 (p < 0.0001). The stone free rates at 1 month of follow-up were 100% for UMP group and 73% for RIRS group. There were insignificant changes to mean hemoglobin and glomerular filtration rate (GFR) in all patients and the average length of the stay was similar in both the groups. The postoperative complications revealed Grade I and II rate of 10% in the UMP group and 35% in the RIRS group, respectively. We concluded that UMP to be safe, effective and more economical to the RIRS for renal stones up to 3 cm in size.Trial registered with ISRCTN registry ID ISRCTN20935105, Retrospective. Urolithiasis published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, HPLC of Formula: 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Falcao, Fatima; Lopes, Carla; Viegas, Erica; Perez, Rita; Aldir, Isabel; Farinha, Helena; Carvalho, Antonio; Mirco, Ana; Marques, Susana; Costa, Tiago Bana E.; Miranda, Ana Claudia; Lebre, Luis; Peixe, Paula; Chagas, Cristina; Mansinho, Kamal; Correia, Jose Manuel published the artcile< Experience of a Portuguese center: effectiveness of direct-acting antiviral therapy for hepatitis C>, Name: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate, the main research area is Antiviral Agents/therapeutic use; Hepacivirus/drug effects; Hepatitis C/drug therapy; Portugal.

Introduction: In late 2014, Portugal implemented a national program for the treatment of patients with chronic hepatitis C with directacting antiviral agents. This program has made Portugal one of the first European countries to implement a structured measure of treatment to eliminate this serious public health problem. The aim of this study was to assess the effectiveness of direct-acting antiviral therapy in the treatment of patients with chronic hepatitis C virus infection. Material and Methods: A retrospective observational study was conducted at Centro Hospitalar de Lisboa Ocidental on the national online platform from Dec. 2014 until Feb. 2017 and included patients with hepatitis C virus infection who underwent treatment. The primary endpoint was sustained virol. response at least 12 wk post treatment. Data was analyzed with the SPSS 17.0 program. Results: During the study period, 820 patients completed therapy and achieved sufficient follow-up time to assess sustained virol. response with an overall response rate of 97.2% (n = 797) and a response rate of 98.0%, 99.5%, 90.9%, 95.1% and 94.2% for genotypes 1a, 1b, 2, 3 and 4, resp. Data suggested that advanced fibrosis (F3/F4), human immunodeficiency virus co-infection and treatment failure with interferon and ribavirin were not neg. related with sustained virol. response in our population. Most patients (80.1%) completed treatment with ledipasvir/sofosbuvir ± ribavirin. The most common adverse events were fatigue and insomnia followed by headache and weight loss. Discussion: Patients predominantly had genotype 1 infection which correlates with HCV distribution in Europe, but we found a major proportion in genotype 4 which can be explained by immigration from African countries. Our patients’ ages ranging from 22 to 90 years, reflected a new approach with no upper age limit. Direct-acting antivirals regimens resulted in remarkably high SVR rates compared to interferon-based regimens, which were consistent with clin. trials data. Conclusion: Our data showed that direct-acting antiviral-based regimens are safe and have a high success rate in the treatment of patients with hepatitis C virus infection in a real-world setting.

Acta Medica Portuguesa published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Name: ((2R,3S,4R,5R)-5-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Ryu, Incheol; Kim, Yoon Ki published the artcile< AU-rich element-mediated mRNA decay via the butyrate response factor 1 controls cellular levels of polyadenylated replication-dependent histone mRNAs>, Formula: C9H13N2O9P, the main research area is mRNA decay AU rich element BRF1 polyadenylated replication histone; ARE-mediated mRNA decay; ELAV like RNA binding protein 1 (ELAVL1); Hu antigen R (HuR); RNA; RNA degradation; RNA metabolism; RNA turnover; RNA-protein interaction; ZFP36 ring finger protein like 1 (ZFP36L1); butyrate response factor 1 (BRF1); histone mRNA biogenesis; mRNA stability; polyadenylation; posttranscriptional regulation; replication-dependent histone mRNA.

Replication-dependent histone (RDH) mRNAs have a nonpolyadenylated 3′-UTR that ends in a highly conserved stem-loop structure. Nonetheless, a subset of RDH mRNAs has a poly(A) tail under physiol. conditions. The biol. meaning of poly(A)-containing (+) RDH mRNAs and details of their biosynthesis remain elusive. Here, using HeLa cells and Western blotting, qRT-PCR, and biotinylated RNA pulldown assays, we show that poly(A)+ RDH mRNAs are post-transcriptionally regulated via adenylate- and uridylate-rich element-mediated mRNA decay (AMD). We observed that the rapid degradation of poly(A)+ RDH mRNA is driven by butyrate response factor 1 (BRF1; also known as ZFP36 ring finger protein-like 1) under normal conditions. Conversely, cellular stresses such as UV C irradiation promoted BRF1 degradation, increased the association of Hu antigen R (HuR; also known as ELAV-like RNA-binding protein 1) with the 3′-UTR of poly(A)+ RDH mRNAs, and eventually stabilized the poly(A)+ RDH mRNAs. Collectively, our results provide evidence that AMD surveils poly(A)+ RDH mRNAs via BRF1-mediated degradation under physiol. conditions.

Journal of Biological Chemistry published new progress about 3′-Untranslated region Role: BSU (Biological Study, Unclassified), BIOL (Biological Study). 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Formula: C9H13N2O9P.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Nardelli, Silvia; Riggio, Oliviero; Rosati, Davide; Gioia, Stefania; Farcomeni, Alessio; Ridola, Lorenzo published the artcile< Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms.>, Computed Properties of 58-97-9, the main research area is Alexithymia; Depression; Directly acting antivirals; Health related quality of life; Hepatitis C virus; State and trait anxiety.

BACKGROUND: Alterations in health-related quality of life (HRQoL) and neuropsychological disorders were described in the hepatitis C virus (HCV) patients. Although several studies investigated the modifications of HRQoL after HCV eradication, no data exists on the modifications of neuropsychological symptoms. AIM: To investigate the effect of directly acting antivirals (DAAs) treatment on HRQoL and neuropsychological symptoms. METHODS: Thirty nine patients with HCV infection underwent a neuropsychological assessment, including Zung-Self Depression-Rating-Scale, Spielberg State-Trait Anxiety Inventory Y1-Y2 and the Toronto-Alexithymia Scale-20 items before and after DAAs treatment. HRQoL was detected by Short-Form-36 (SF-36). RESULTS: All HRQoL domains, but role limitation physical and bodily pain, significantly improved after treatment. Interestingly, after DAAs treatment, all domains of HRQoL returned similar to those of controls. Each neuropsychological test significantly improved after HCV eradication. A significant correlation was observed among each psychological test and the summary components of SF-36. At multiple linear regression analysis including each psychological test as possible covariates, Zung-Self Depression Rating Scale (Zung-SDS) score was independently and significantly related to summary components of the SF-36 in the basal state and the difference between Zung-SDS score before and after treatment was the only variable significantly and independently related to the modification of HRQoL induced by the treatment. CONCLUSION: Neuropsychological symptoms strongly influenced HRQoL in HCV patients and there was a significant improvement of neuropsychological tests and HRQoL after DAAs treatment.

World journal of gastroenterology published new progress about 58-97-9. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Computed Properties of 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

El-Baraky, Iman A.; Abbassi, Maggie M.; Ebeid, Fatma S.; Hassany, Mohamed; Sabry, Nirmeen A.; El-Sayed, Manal H. published the artcile< Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients>, Electric Literature of 58-97-9, the main research area is beta thalassemia major sofosbuvir ledipasvir Hepatitis C virus; Hepatitis C virus; Ledipasvir; Pharmacokinetics; Sofosbuvir; Thalassemia.

Hepatitis C virus (HCV) infected adolescents with beta-thalassemia major (BTM) are considered a potential population for HCV micro-elimination model development where BTM may neg. impact the pharmacokinetic exposure parameters of sofosbuvir/ledipasvir (SOF/LED).The study aimed at studying the effect of BTM on SOF/LED and SOF metabolite (GS-331007) pharmacokinetics.A prospective, controlled study recruiting BTM and control HCV infected adolescents (Clinicaltrials.gov identifier-NCT04353986). Pharmacokinetic exposure to GS-331007 and LED was the primary pharmacokinetic outcome. No-effect boundaries were set to 90confidence interval (CI) of exposure geometric mean ratio (GMR) within 70-143. Dose suitability was based on the 90CI of exposure GMR within 50-200compared to adults. The percentage of patients achieving sustained virol. response 12 wk post-treatment (SVR12) was the primary efficacy endpoint.Thirteen patients were enrolled per study group. All patients were included in the pharmacokinetic anal. (n=26). BTM patients showed lower GS-331007 and LED exposure that could, resp., be as low as 45.4and 36.1compared to their control group. GS-331007 exposure in BTM patients was nearly half (56.8, 90CI 45.3-71.2) that observed in adults. Despite that low drug exposure in 46.2of BTM patients may alert dose unsuitability, they achieved SVR12. Moreover, patients with total bilirubin ≥1.93 mg/dL were predicted to have low GS-331007 exposure (0.913 receiver operating characteristic area under the curve with sensitivity and specificity >80).The identified systematically lower drug exposure in BTM patients might partially explain relapses or treatment failures among BTM patients reported in other studies. BTM may be a hurdle towards implementing HCV micro-elimination model that may necessitate dose-adjustment.

Clinics and Research in Hepatology and Gastroenterology published new progress about Geometric phase. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Electric Literature of 58-97-9.

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem